Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | AVPR1A | P37288 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9615977 | 0.86 | SIGMAR1 (0.54) | OPRD1SIGMAR1AVPR1A | |
| SCHEMBL3403510 | 0.82 | SIGMAR1 (0.55) | OPRD1SIGMAR1AVPR1A | |
| SCHEMBL11328335 | 0.81 | SIGMAR1 (0.50) | OPRD1SIGMAR1 | |
| SCHEMBL30389740 | 0.81 | SIGMAR1 (0.50) | OPRD1SIGMAR1 | |
| SCHEMBL3400315 | 0.79 | SIGMAR1 (0.49) | OPRD1SIGMAR1AVPR1A | |
| SCHEMBL29790950 | 0.79 | SIGMAR1 (0.49) | OPRD1SIGMAR1AVPR1A | |
| SCHEMBL31415656 | 0.78 | SIGMAR1 (0.53) | OPRD1SIGMAR1AVPR1A | |
| SCHEMBL15963043 | 0.78 | SIGMAR1 (0.48) | OPRD1SIGMAR1AVPR1A | |
| SCHEMBL8871048 | 0.78 | SIGMAR1 (0.53) | OPRD1SIGMAR1AVPR1A | |
| SCHEMBL86971 | 0.78 | SIGMAR1 (0.53) | OPRD1SIGMAR1AVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040220223-A1 | Novel human NK3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2004-11-04 | — | — | US | claimed |
| US-20020049329-A1 | Novel human NK3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2002-04-25 | — | — | US | claimed |
| US-6291672-B1 | FOR THE PREPARATION OF DRUGS USEFUL IN THERAPY OF PSYCHIATRIC DISEASES, DISEASES OF PSYCHOSOMATIC ORIGIN, HYPERTENSION | SANOFI-SYNTHELABO (FR) | 2001-09-18 | — | — | US | claimed |
| US-6028082-A | FOR TRATING PSYCHOLOGICAL DISORDERS | SANOFI-SYNTHELABO (FR) | 2000-02-22 | — | — | US | claimed |
| EP-0630887-B1 | 4-(aryl-substituted)-piperidines as neurokinin receptor antagonists | ZENECA LTD (GB) | 1999-07-28 | — | — | EP | claimed |
| US-5654299-A | TREATING RESPIRATORY SYSTEM DISORDER (I.E. ASTHMA) WITH NEUROKININ 2 RECEPTOR ANTAGONIST | ZENECA LIMITED (GB) | 1997-08-05 | — | — | US | claimed |
| EP-0630887-A1 | 4-(aryl-substituted)-piperidines as neurokinin receptor antagonists | ZENECA LIMITED (GB) | 1994-12-28 | — | — | EP | claimed |
| US-20230158039-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2023-05-25 | — | — | US | disclosed |
| US-20210188758-A1 | PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS | VTVX HOLDINGS II LLC | 2021-06-24 | — | — | US | disclosed |
| US-10947180-B2 | Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists | VTV THERAPEUTICS LLC (US) | 2021-03-16 | — | — | US | disclosed |
| US-20210070756-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2021-03-11 | — | — | US | disclosed |
| US-20200291027-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2020-09-17 | — | — | US | disclosed |
| US-20200215073-A1 | PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS | HIGH POINT PHARMACEUTICALS, LLC | 2020-07-09 | — | — | US | disclosed |
| EP-1878721-A1 | 4-Piperidylbenzamides as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors | NOVO NORDISK A/S (DK) | 2008-01-16 | — | — | EP | disclosed |
| WO-2007125105-A2 | BENZAMIDE GLUCOKINASE ACTIVATORS | TRANSTECH PHARMA, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007125103-A2 | BENZAMIDE GLUCOKINASE ACTIVATORS | TRANSTECH PHARMA, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007068718-A1 | POLYPEPTIDE PROTRACTING TAGS | NOVO NORDISK A/S (DK) | 2007-06-21 | — | — | WO | disclosed |
| US-6710042-B2 | PIPERIDINE DERIVATIVES; TREATMENT OF PSYCHOLOGICAL DISORDERS | SANOFI-SYNTHELABO (FR) | 2004-03-23 | — | — | US | disclosed |
| US-20020049329-A1 | Novel human NK3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2002-04-25 | — | — | US | disclosed |
| US-6291672-B1 | FOR THE PREPARATION OF DRUGS USEFUL IN THERAPY OF PSYCHIATRIC DISEASES, DISEASES OF PSYCHOSOMATIC ORIGIN, HYPERTENSION | SANOFI-SYNTHELABO (FR) | 2001-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220223-A1 | Novel human NK3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them | TACR2, BDKRB2, ACKR3 | OPRD1 249/4885SIGMAR1 919/4885AVPR1A 200/4885 |
| US-20200291027-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | BRD3, BRD4, BRD1 | OPRD1 2261/4885SIGMAR1 3020/4885AVPR1A 1779/4885 |
| US-20210070756-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | BRD3, BRD4, BRD1 | OPRD1 2261/4885SIGMAR1 3020/4885AVPR1A 1779/4885 |
| US-20020049329-A1 | Novel human NK3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them | TACR2, BDKRB2, ACKR3 | OPRD1 249/4885SIGMAR1 919/4885AVPR1A 200/4885 |
| US-20230158039-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | OPRD1 1665/4885SIGMAR1 2095/4885AVPR1A 1825/4885 |
| US-10947180-B2 | Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists | PPARG, PPARA, PPARD | OPRD1 430/4885SIGMAR1 1906/4885AVPR1A 1835/4885 |
| US-20200215073-A1 | PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS | PPARG, PPARA, PPARD | OPRD1 430/4885SIGMAR1 1906/4885AVPR1A 1835/4885 |
| US-20210188758-A1 | PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS | PPARG, PPARA, PPARD | OPRD1 430/4885SIGMAR1 1906/4885AVPR1A 1835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.